Boyer David W. sold 3,888 shares of NEUROCRINE BIOSCIENCES INC at $156.64 for −$609k on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Chief Corp. Affairs Officer
Chief Corp. Affairs Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$609,023.32Shares × reported price
Shares traded
3,888Common Stock
Price per share
$156.64Reported price. Read footnotes for ranges.
% of reported position traded
33.27%This security and ownership context
Holdings after
7,799Direct
Trade date
May 26, 2026Sell
Filed
May 28, 2026, 6:08 PM ET2-day reporting delay
Accession
0001909817-26-000007Code S · Transaction 387835
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 11,687 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Related trades are temporarily unavailable. Open the SEC filing for the complete report, or reload this page.

NBIX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
NBIX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −18%1w ago −1.3%1d ago +0.2%
Returns since7d +7%30d +7.8%90d +0.1%180d1y

Footnotes in full

F1: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $155.81 to $157.62. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3: Includes an aggregate of 106 shares purchased on February 27, 2026 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan.